SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced ...
The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients ...
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year.New, potentially bes ...
University of Maryland researchers are developing a vaccine that targets the dangerous foodborne bug, Salmonella.
Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting ...
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage ...
OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA ...
We retrospectively analyzed 11 TACC specimens from the pathology archives of two Italian cancer reference centers. TROP-2 expression was assessed in all cases using immunohistochemistry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback